Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of mortality and morbidity in patients with chronic heart failure.
Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Pocock SJ, et al. Among authors: ostergren j. Eur Heart J. 2006 Jan;27(1):65-75. doi: 10.1093/eurheartj/ehi555. Epub 2005 Oct 11. Eur Heart J. 2006. PMID: 16219658
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. McMurray JJ, et al. Among authors: ostergren j. Lancet. 2003 Sep 6;362(9386):767-71. doi: 10.1016/S0140-6736(03)14283-3. Lancet. 2003. PMID: 13678869 Clinical Trial.
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA. O'Meara E, et al. Among authors: ostergren j. Eur J Heart Fail. 2005 Jun;7(4):650-6. doi: 10.1016/j.ejheart.2005.01.021. Eur J Heart Fail. 2005. PMID: 15921807 Free article.
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators. O'Meara E, et al. Among authors: ostergren j. Circulation. 2006 Feb 21;113(7):986-94. doi: 10.1161/CIRCULATIONAHA.105.582577. Epub 2006 Feb 13. Circulation. 2006. PMID: 16476847
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. McMurray JJ, et al. Among authors: ostergren j. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2006.02.028. Am Heart J. 2006. PMID: 16644319
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, Vanhaecke J, van Veldhuisen DJ, Ostergren J, Granger CB, Yusuf S, Pfeffer MA, Swedberg K. McMurray JJ, et al. Among authors: ostergren j. Eur Heart J. 2006 Jun;27(12):1447-58. doi: 10.1093/eurheartj/ehl016. Eur Heart J. 2006. PMID: 16754631 Clinical Trial.
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.
Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG; CHARM Investigators and Committees. Hawkins NM, et al. Among authors: ostergren j. Eur J Heart Fail. 2007 May;9(5):510-7. doi: 10.1016/j.ejheart.2006.11.006. Epub 2007 Feb 20. Eur J Heart Fail. 2007. PMID: 17317308 Free article.
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. O'Meara E, et al. Among authors: ostergren j. Circulation. 2007 Jun 19;115(24):3111-20. doi: 10.1161/CIRCULATIONAHA.106.673442. Epub 2007 Jun 11. Circulation. 2007. PMID: 17562950 Clinical Trial.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. MacDonald MR, et al. Among authors: ostergren j. Eur Heart J. 2008 Jun;29(11):1377-85. doi: 10.1093/eurheartj/ehn153. Epub 2008 Apr 14. Eur Heart J. 2008. PMID: 18413309 Clinical Trial.
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB. Pocock SJ, et al. Among authors: ostergren j. Eur Heart J. 2008 Nov;29(21):2641-50. doi: 10.1093/eurheartj/ehn420. Epub 2008 Sep 26. Eur Heart J. 2008. PMID: 18819960 Clinical Trial.
218 results